The Report “PharmaPoint: Neuropathic
Pain – Japan Drug Forecast and Market Analysis to 2022″ by Globaldata Group is
now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with “PharmaPoint: Neuropathic Pain – Japan
Drug Forecast and Market Analysis to 2022″ in subject line and your contact
details to purchase this report or get your questions answered.
Neuropathic
pain (NP) is defined as a disorder of the sensorimotor system and is distinctly
different from nociceptive pain, which is a consequence of trauma, injury, or
inflammation. The main difference between neuropathic and nociceptive pain is
the absence of a continuous nociceptive input in neuropathic pain. Although the
term neuropathic pain is used to describe a wide range of pain syndromes with
varying etiologies, this report focuses on 3 distinct forms of NP: Painful
diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia. The main
classes of drugs used to treat these three neuropathic pain indications include
anticonvulsants, antidepressants, opioids and topical treatments. However,
despite the availability of multiple pain medications only 50% of patients
respond to any given drug and there are numerous the side effects associated
particularly with systemically administered drugs, that reduce their
tolerability.
Similar
to the rest of the global markets, this will be fueled predominantly by the
growing incidence of NP as a result of the increasing elderly population, which
is even more pronounced in Japan. However, unlike the other countries in the
7MM, most of the growth in the NP market in Japan will not be due to the entry
of numerous pipeline drugs, but rather will be the result of the delayed launch
and continued growth of both Lyrica and Cymbalta. Both these drugs launched in
Japan approximately five years after their launch in the US and EU.
Furthermore, both drugs are subject to extended exclusivity in Japan, with the
patent for Lyrica not set to expire in Japan until 2022, and the post-marketing
exclusivity for Cymbalta estimated to extend to 2017.
Request Sample copy of this
report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=173904 .
Scope
§ Overview of Neuropathic Pain including
epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines
as well as an overview on the competitive landscape.
§ Detailed information on the key drugs in Japan
including product description, safety and efficacy profiles as well as a SWOT
analysis.
§ Sales forecast for the top drugs in Japan from
2012-2022.
§ Analysis of the impact of key events as well
the drivers and restraints affecting the Japan Neuropathic Pain market.
Reasons
to buy
§ Understand and capitalize by identifying
products that are most likely to ensure a robust return
§ Stay ahead of the competition by understanding
the changing competitive landscape for Neuropathic Pain.
§ Effectively plan your M&A and partnership
strategies by identifying drugs with the most promising sales potential
§ Make more informed business decisions from
insightful and in-depth analysis of drug performance
§ Obtain sales forecast for drugs from 2012-2022
in Japan.
Complete
report is available @ http://www.rnrmarketresearch.com/pharmapoint-neuropathic-pain-japan-drug-forecast-and-market-analysis-to-2022-market-report.html .
Table of Contents
1 Table of Contents 5
1.1 List of Tables 9
1.2 List of Figures 11
1.1 List of Tables 9
1.2 List of Figures 11
2 Introduction 12
2.1 Catalyst 12
2.2 Related Reports 12
2.1 Catalyst 12
2.2 Related Reports 12
3 Disease Overview 14
3.1 Clinical Manifestations of Neuropathic Pain - Signs and Symptoms 16
3.1.1 Painful Diabetic Neuropathy 18
3.1.2 Postherpetic Neuralgia 19
3.1.3 Trigeminal Neuralgia 19
3.2 Etiology and Pathophysiology 20
3.2.1 Etiology 21
3.2.2 Pathophysiology 22
3.1 Clinical Manifestations of Neuropathic Pain - Signs and Symptoms 16
3.1.1 Painful Diabetic Neuropathy 18
3.1.2 Postherpetic Neuralgia 19
3.1.3 Trigeminal Neuralgia 19
3.2 Etiology and Pathophysiology 20
3.2.1 Etiology 21
3.2.2 Pathophysiology 22
4 Disease Management 30
4.1 Diagnosis and Treatment Overview 30
4.1 Diagnosis and Treatment Overview 30
For further information on “PharmaPoint: Neuropathic Pain – Japan Drug Forecast and Market Analysis
to 2022” report OR for any other business research / market intelligence
need on the ‘pharmaceuticals’ market
(http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals . ),
contact sales@rnrmarketresearch.com /
Call +1 888 391 5441.
About Us:
RnRMarketResearch.com is an online market research
reports library of 250,000+ in-depth studies of over 5000 micro markets. Our
database includes reports by leading publishers from across the globe. We
provide 24/7 online and offline support service to our customers. RnR Market
Research also offers company data, country profiles, trends, information and
analysis on the sector of your interest.
You
can also reach us @
No comments:
Post a Comment
Note: only a member of this blog may post a comment.